NasdaqGS - Delayed Quote USD
Amgen Inc. (AMGN)
275.84
+5.40
+(2.00%)
At close: May 7 at 4:00:00 PM EDT
271.81
-4.03
(-1.46%)
Pre-Market: 5:39:20 AM EDT
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
34,126,000
33,424,000
28,190,000
26,323,000
25,979,000
Cost of Revenue
12,626,000
12,858,000
8,451,000
6,406,000
6,454,000
Gross Profit
21,500,000
20,566,000
19,739,000
19,917,000
19,525,000
Operating Expense
14,055,000
13,308,000
11,842,000
10,351,000
10,381,000
Operating Income
7,445,000
7,258,000
7,897,000
9,566,000
9,144,000
Net Non Operating Interest Income Expense
-3,054,000
-3,155,000
-2,875,000
-1,406,000
-1,197,000
Other Income Expense
2,259,000
506,000
2,833,000
-814,000
-1,246,000
Pretax Income
6,650,000
4,609,000
7,855,000
7,346,000
6,701,000
Tax Provision
717,000
519,000
1,138,000
794,000
808,000
Net Income Common Stockholders
5,933,000
4,090,000
6,717,000
6,552,000
5,893,000
Diluted NI Available to Com Stockholders
5,933,000
4,090,000
6,717,000
6,552,000
5,893,000
Basic EPS
11.05
--
12.56
12.18
10.34
Diluted EPS
10.97
--
12.49
12.11
10.28
Basic Average Shares
537,500
--
535,000
538,000
570,000
Diluted Average Shares
542,250
--
538,000
541,000
573,000
Total Operating Income as Reported
7,445,000
7,258,000
7,897,000
9,566,000
7,639,000
Total Expenses
26,681,000
26,166,000
20,293,000
16,757,000
16,835,000
Net Income from Continuing & Discontinued Operation
5,933,000
4,090,000
6,717,000
6,552,000
5,893,000
Normalized Income
5,933,000
4,090,000
6,717,000
6,552,000
7,215,895
Interest Expense
3,054,000
3,155,000
2,875,000
1,406,000
1,197,000
Net Interest Income
-3,054,000
-3,155,000
-2,875,000
-1,406,000
-1,197,000
EBIT
9,704,000
7,764,000
10,730,000
8,752,000
7,898,000
EBITDA
15,284,000
13,356,000
14,801,000
12,169,000
11,296,000
Reconciled Cost of Revenue
12,626,000
12,858,000
8,451,000
6,406,000
6,454,000
Reconciled Depreciation
5,580,000
5,592,000
4,071,000
3,417,000
3,398,000
Net Income from Continuing Operation Net Minority Interest
5,933,000
4,090,000
6,717,000
6,552,000
5,893,000
Total Unusual Items Excluding Goodwill
--
--
0
0
-1,505,000
Total Unusual Items
--
--
0
0
-1,505,000
Normalized EBITDA
15,284,000
13,356,000
14,801,000
12,169,000
12,801,000
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
0
0
0
0
-182,105
12/31/2021 - 6/17/1983
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
ABBV AbbVie Inc.
188.09
+0.50%
MRK Merck & Co., Inc.
79.12
+0.10%
BMY Bristol-Myers Squibb Company
47.62
+0.11%
GILD Gilead Sciences, Inc.
98.90
+1.04%
BIIB Biogen Inc.
117.21
+0.33%
JNJ Johnson & Johnson
157.30
+1.83%
LLY Eli Lilly and Company
776.72
+0.21%
NVO Novo Nordisk A/S
67.55
+1.90%
PFE Pfizer Inc.
22.79
-0.39%
OGN Organon & Co.
8.76
-4.05%